Alzheimer's Prevention in 2025: Blood Tests, Early Detection, and What You Can Actually Control
Asare B. Christian, MD, MPH · 2026-10-10
Alzheimer's Prevention in 2025: Blood Tests, Early Detection, and What You Can Actually Control
The Short Answer
Alzheimer's prevention entered a genuinely new phase in 2025. Blood tests for phosphorylated tau 217 can now identify who will develop cognitive impairment years before symptoms appear, tau imaging is defining a precise early-treatment window, and midlife hormonal changes have been linked to measurable brain aging. Prevention increasingly means early, personalized risk assessment combined with exercise and metabolic care, not waiting for memory loss to begin.
What the Evidence Shows
A blood test predicted cognitive decline ten years ahead
A prospective study published in Alzheimer's & Dementia in 2025 followed symptom-free older adults for a decade. Elevated baseline plasma p-tau217, a blood biomarker of Alzheimer's pathology, accurately identified who would later develop cognitive impairment [1]. The biomarker detected preclinical disease long before clinical symptoms. A positive result is not a diagnosis, but it is a powerful signal that prevention deserves immediate attention.
Tau imaging defined the treatment window
A multi-cohort study in Nature Neuroscience mapped tau accumulation using PET imaging in people with and without cognitive impairment. Early tau accumulation in specific cortical regions marked the critical transition toward clinical progression, even in people who felt entirely normal [2]. That stage is where future disease-modifying therapy is most likely to help.
Midlife menopause changes connect to brain aging
A proteomic study in Nature Medicine analyzed blood proteins across the menopausal transition and linked specific midlife protein shifts to brain aging and dementia risk [3]. The work positions midlife as a measurable, actionable window for brain protection, and it connects two fields, hormone health and neurology, that too often operate separately.
Exercise modified the disease even after pathology began
A longitudinal study in Nature Medicine combined objective activity monitoring with amyloid and tau biomarkers in older adults with preclinical Alzheimer's changes. Higher daily physical activity was associated with slower tau accumulation and less cognitive decline, even in people with elevated amyloid [4]. Exercise actively modifies disease trajectory in the silent, earliest stage.
Clinical Interpretation
The practical sequence for a motivated patient is now concrete: quantify risk early through clinical assessment and, when appropriate, biomarker testing; address modifiable drivers, including metabolic health, sleep, hearing, and cardiovascular risk; maintain genuinely high levels of physical activity; and re-evaluate longitudinally. Blood-based biomarkers are moving the field from reaction to anticipation.
Limitations and Uncertainties
Biomarker positivity is not a diagnosis and carries real psychological weight; testing belongs in a counseling context. Anti-amyloid therapies carry infusion-related risks and are appropriate only for carefully selected patients with confirmed early disease, under specialist care. Observational findings, including the hormone and exercise studies, show associations and cannot alone prove causation.
Who This Applies To
Adults with a family history of dementia, subjective memory concerns, early menopause, metabolic risk factors, or simply a proactive approach to brain health are reasonable candidates for evaluation. People already diagnosed with mild cognitive impairment need specialist-coordinated care.
How Aether Medicine Approaches Brain Health
Within our ASSESS, RESTORE, OPTIMIZE framework, brain health evaluation includes metabolic and vascular risk assessment, hormone evaluation where relevant, cognitive screening, and lifestyle systems with longitudinal tracking, coordinated with neurology when specialty care is indicated.
Frequently Asked Questions
Should I get a p-tau217 blood test?
It depends on your risk profile and what you would do with the result. For someone with family history or concerning symptoms, early information can direct prevention. Testing is best done with medical counseling before and after.
Can Alzheimer's actually be prevented?
Risk can be meaningfully reduced, not eliminated. Large population analyses attribute a substantial share of dementia risk to modifiable factors. Prevention is about lowering risk early and consistently.
Does exercise help even if amyloid is already present?
The 2025 evidence suggests yes: activity level was associated with slower tau accumulation and better cognition even among people with preclinical pathology.
I had early menopause. Is my brain health at risk?
Early menopause is associated with subtle cognitive differences in large cohorts, and midlife proteomic shifts are now measurable. This is a reason for proactive brain and hormone evaluation, not alarm.
Where can I get preventive brain health care near Philadelphia?
Aether Medicine is located at 660 American Ave, #103, King of Prussia, PA 19406, serving the Main Line and Greater Philadelphia. Call 484-806-1101 to discuss a consultation.
References
- Yakoub Y, et al. Plasma p-tau217 identifies cognitively normal older adults who will develop cognitive impairment in a 10-year window. Alzheimers Dement. 2025. https://doi.org/10.1002/alz.14537
- Ossenkoppele R, et al. Tau PET positivity in individuals with and without cognitive impairment. Nat Neurosci. 2025. https://doi.org/10.1038/s41593-025-02000-6
- Wood AM, et al. Blood proteomics of menopause map to brain aging and dementia risk. Nat Med. 2026. https://doi.org/10.1038/s41591-026-04648-4
- Yau SY, et al. Physical activity as a modifiable risk factor in preclinical Alzheimer's disease. Nat Med. 2025. https://doi.org/10.1038/s41591-025-03955-6
About the Author
Asare B. Christian, MD, MPH, ABPMR, ABAARM, is Founder and Medical Director of Aether Medicine, double board-certified in Physical Medicine and Rehabilitation and Anti-Aging and Regenerative Medicine, with training at Johns Hopkins and Harvard Medical School. He serves as a Voting Member of the U.S. FDA Pharmacy Compounding Advisory Committee (PCAC), term 2026-2030. This federal advisory role is separate from Aether Medicine's commercial services and does not imply FDA endorsement of the practice or any therapy.
Brain Health Deserves a Plan, Not Just a Hope
If you want a proactive, evidence-based brain health evaluation in King of Prussia, the Main Line, or Greater Philadelphia, call 484-806-1101 or visit https://aethermedicine.com.
Educational information only. This article is a draft for physician review and is not individualized medical advice. Consult your physician before starting, stopping, or changing any treatment.